Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Related Keywords

Mazyar Shadman ,Fred Hutch Cancer Center ,Network Endowed Chair ,Zanubrutinib ,B Cell Malignancies ,Phase 2 Bgb 3111 215 Study ,Intolerant To Acalabrutinib ,Nash Meeting ,